Experimental Hematology & Oncology

Article	Citations
Construction and characterization of chimeric FcγR T cells for universal T cell therapy	132
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	129
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	114
Cell membrane patches transfer CAR molecules from a cellular depot to conventional T cells for constructing innovative fused-CAR-T cells without necessitating genetic modification	107
The roles of tissue resident macrophages in health and cancer	95
ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells	91
Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome	74
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers	70
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting	61
Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment	58
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling	56
ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma	55
Age-related accumulation of B-1 cell progenitors in mice reflects changes in miR15a/16-1 expression and radioresistance capacity	52
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera	47
Sphingosine kinase 1 contributes to the metastatic potential of epithelial ovarian cancer to the adipocyte-rich niche	47
Mutational signatures of synchronous and metachronous brain metastases from lung adenocarcinoma	46
Spliceosome inhibitor induces human hematopoietic progenitor cell reprogramming toward stemness	45
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	45
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	45
Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development	45
CD44 promotes hepatocellular carcinoma progression via upregulation of YAP	45
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials	44
A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease	42
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	42
CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro	40

cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	39
CUL4A-DDB1-circRFWD2 E3 ligase complex mediates the ubiquitination of p27 to promote multiple myeloma proliferation	39
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation	38
Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia	37
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	34
Correction: ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer	33
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	33
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	33
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	33
Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	32
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	31
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	30
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development	30
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	30
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	29
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target	27
CircFBXW7 in patients with T-cell ALL: depletion sustains MYC and NOTCH activation and leukemia cell viability	27
Targeting the integrated stress response in hematologic malignancies	27
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	27
Focal adhesion kinase: from biological functions to therapeutic strategies	26
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	26
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy	26
TRIM family contribute to tumorigenesis, cancer development, and drug resistance	26
Chimeric antigen receptor engineered natural killer cells for cancer therapy	25
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	25
Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma	25
Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain	24
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner	24
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	24
Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis	23
A proinflammatory response and polarized differentiation of stromal elements characterizes the murine myeloma bone marrow niche	23
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies	23
CAR-T cell combination therapies in hematologic malignancies	23
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	22
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	22
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	22
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases	22
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities	22
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	21
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	21
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	20
1q jumping translocation as a biomarker in myeloid malignancy: frequently mutated genes associated with bad prognosis and low survival	20
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	20
Function and clinical significance of N6-methyladenosine in digestive system tumours	20
Transfer RNA-derived small RNA: an emerging small non-coding RNA with key roles in cancer	20
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis	20
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications	19
GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment	19
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	19
COVID-19 vaccination associated severe immune thrombocytopenia	19

MSCsDB: a database of single-cell transcriptomic profiles and in-depth comprehensive analyses of human mesenchymal stem cells	18
Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients	18
Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic impli	18
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases	18
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas	18
Cell competition between wild-type and JAK2V617F mutant cells prevents disease relapse after stem cell transplantation in a murine model of myeloproliferative neoplasm	17
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	17
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation	17
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors	17
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis	17
CTP synthase 2 predicts inferior survival and mediates DNA damage response via interacting with BRCA1 in chronic lymphocytic leukemia	16
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA	16
CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis	16
GPR109A controls neutrophil extracellular traps formation and improve early sepsis by regulating ROS/PAD4/Cit-H3 signal axis	16
ANXA6/TRPV2 axis promotes lymphatic metastasis in head and neck squamous cell carcinoma by inducing autophagy	15
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer	15
Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting	15
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates	15
Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice	15
LINP1 represses unfolded protein response by directly inhibiting eIF2α phosphorylation to promote cutaneous squamous cell carcinoma	15
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer	14
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	14
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	14
Secretogranin II influences the assembly and function of MHC class I in melanoma	14
NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice	14
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance	13
Analysis of CD20 and PD-L1 levels on small extracellular vesicles (sEV) produced by DLBCL cells and EBV-transformed B cells, and potential role in T cell inhibition	13
Nuclear porcupine mediates XRCC6/Ku70 S-palmitoylation in the DNA damage response	13
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma	13
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies	13
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies	13
Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution	12
Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer	12
Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/re	12
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma	12
Regulatory T cells contribute to the immunosuppressive phenotype of neutrophils in a mouse model of chronic lymphocytic leukemia	12
Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis	12
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies	12
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors	12
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	12
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC	12
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information	11
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression	11
Current insight into the regulation of PD-L1 in cancer	11
Bridging therapy with histotripsy prior to liver transplantation for hepatocellular carcinoma: a first case report	11
Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells	11
Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation	11
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	11
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia	11
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	10
ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer	10
Breast cancer heterogeneity and its implication in personalized precision therapy	10
METTL1 mediated tRNA m7G modification promotes leukaemogenesis of AML via tRNA regulated translational control	10
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy	10
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy	10
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect	10
Role of m6A writers, erasers and readers in cancer	10
Roles of the intestinal microbiota and microbial metabolites in acute GVHD	10
High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma	10
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	10
Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells	10
The gut microbiota as a booster for radiotherapy: novel insights into radio-protection and radiation injury	10
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance	9
Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis	9
Challenges and strategies associated with CAR-T cell therapy in blood malignancies	9
A non-conditioned bone marrow transplantation mouse model to study clonal hematopoiesis and myeloid malignancies	9
Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium	9
Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells	9
Follow our path with asparaginase activity: one technique, but different uses in clinical practice	9
Low expression of PEBP1P2 promotes metastasis of clear cell renal cell carcinoma by post-transcriptional regulation of PEBP1 and KLF13 mRNA	9
Radiation-induced exosomal miR-21 enhances tumor proliferation and invasiveness in breast cancer: implications for poor prognosis in radiotherapy patients	9
Strain-dependent modifiers exacerbate familial leukemia caused by GATA1-deficiency	8
Calcium oxalate crystals trigger epithelial-mesenchymal transition and carcinogenic features in renal cells: a crossroad between kidney stone disease and renal cancer	8
The immunometabolic landscape of the bone marrow microenvironment in acute myeloid leukemia	8
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting	8
Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China	8
Disrupting Notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses	8
Three-dimensional chromatin landscapes in MLLr AML	8
Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma	8
A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis	8

Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia	8
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	8
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	8
Enhanced depletion of MLL-fusion proteins in acute leukemia: potential for improved therapeutic outcomes	8
Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort	8
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study	8
Correction to: Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies	8
The metabolic adaptation mechanism of metastatic organotropism	8
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing	8
PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma	8
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	8
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	8
Heat-killed Prevotella intermedia promotes the progression of oral squamous cell carcinoma by inhibiting the expression of tumor suppressors and affecting the tumor microenvironment	8
Advances in nano-immunotherapy for hematological malignancies	7
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy	7
Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer	7
Exosomal PD-L1 and lactate versus tissue PD-L1 as biomarkers for clinical outcomes of PD-1 Blockade plus chemotherapy in metastatic esophagogastric signet ring cell carcinoma	7
Recent advances in Lynch syndrome	7
Identification of a novel NPM1 mutation in acute myeloid leukemia	7
TCR engineered T cells for solid tumor immunotherapy	7
Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy	7
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer	7
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	7
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	7
Molecular profiling of skin cells identifies distinct cellular signatures in radiation-induced skin injury across various stages in the murine dataset	7
Single VHH-directed BCMA CAR-NK cells for multiple myeloma	6
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	6
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors	6
TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model	6
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	6
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses	6
Dlk1 maintains adult mice long-term HSCs by activating Notch signaling to restrict mitochondrial metabolism	6
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer	6
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment	6
TLR7/8 signaling activation enhances the potency of human pluripotent stem cell-derived eosinophils in cancer immunotherapy for solid tumors	6
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways	6
Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns	6
The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications	6
m6A binding protein YTHDF2 in cancer	6
Alcohol accelerates the development of esophageal squamous cell carcinoma through elevated Gram-negative bacteria in peripheral circulation	6
Hematopoietic stem/progenitor cell transplantation recovers immune defects and prevents lymphomas in Atm-deficient mice	6
Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside	6
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination	5
IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis	5
Identification of a novel subtype of SPP1 + macrophages expressing SIRPα: implications for tumor immune evasion and treatment response prediction	5
Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism	5
JOSD2 regulates PKM2 nuclear translocation and reduces acute myeloid leukemia progression	5
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia	5
Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia	5
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia	5
Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells	5
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	5
Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine	5
A novel E-cadherin/SOX9 axis regulates cancer stem cells in multiple myeloma by activating Akt and MAPK pathways	5
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma	5
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification	5
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response	5
A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma	5
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma	5
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting	5
CUL4B-DDB1-COP1-mediated UTX downregulation promotes colorectal cancer progression	5